Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have earned an average recommendation of “Moderate Buy” from the nineteen brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, thirteen have issued a buy rating and three have issued a strong buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $38.4118.

A number of brokerages have commented on DYN. Robert W. Baird set a $30.00 price objective on shares of Dyne Therapeutics in a research report on Monday, December 8th. TD Cowen restated a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, December 8th. Tudor Pickering set a $23.00 target price on Dyne Therapeutics in a research report on Tuesday, December 9th. JPMorgan Chase & Co. reduced their price target on Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating for the company in a report on Tuesday, January 20th. Finally, Sanford C. Bernstein set a $23.00 price objective on Dyne Therapeutics in a report on Tuesday, December 9th.

Dyne Therapeutics Stock Up 4.9%

DYN opened at $18.76 on Tuesday. Dyne Therapeutics has a 52 week low of $6.36 and a 52 week high of $25.00. The business has a 50 day moving average price of $19.05 and a two-hundred day moving average price of $16.21. The company has a quick ratio of 13.47, a current ratio of 13.47 and a debt-to-equity ratio of 0.14. The company has a market cap of $2.68 billion, a PE ratio of -5.13 and a beta of 1.30.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Wednesday, November 5th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.05. As a group, research analysts anticipate that Dyne Therapeutics will post -3.44 EPS for the current year.

Institutional Trading of Dyne Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Chung Wu Investment Group LLC acquired a new position in Dyne Therapeutics during the third quarter worth about $30,000. Strs Ohio purchased a new stake in shares of Dyne Therapeutics during the 4th quarter worth approximately $51,000. CWM LLC grew its holdings in shares of Dyne Therapeutics by 168.1% in the 2nd quarter. CWM LLC now owns 3,030 shares of the company’s stock worth $29,000 after acquiring an additional 1,900 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Dyne Therapeutics by 25.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock valued at $70,000 after purchasing an additional 1,109 shares in the last quarter. Finally, Ameritas Investment Partners Inc. raised its holdings in Dyne Therapeutics by 11.1% during the second quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company’s stock worth $91,000 after purchasing an additional 955 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.